In Brief: Environmental assessments
Environmental assessments: Categorical exclusions will be granted for drug applications that do not result in increase of active moiety use or in increases at a concentration in the environment of less than one part per billion, according to FDA's proposed rule to amend its regulations under the National Environmental Policy Act of 1969. The changes published in the April 3 Federal Register implement the Clinton Administration's Reinventing Drug and Medical Device Regulations initiative announced in April 1995 ("The Pink Sheet" April 10, 1995, p. 9). Also covered by the exclusions are INDs, antibiotic and insulin batch testing, and lot release testing for biologics. Environmental assessments still will be required for products that pose "serious harm" to the environment or that "adversely affect" a habitat or species covered by the Endangered Species Act...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth